Common Mistakes in Trial Results Reporting and How to Fix Them

Introduction: Importance of Accurate Results Reporting

Accurate reporting of clinical trial results on public registries such as ClinicalTrials.gov and the EU Clinical Trials Information System (CTIS) is a regulatory and ethical obligation. However, due to differences in data structure, formatting requirements, and limited internal QC, sponsors often make avoidable mistakes. These can lead to public queries, regulatory penalties, or inspection findings.

This article outlines the most common reporting errors and provides practical guidance on how to detect, correct, and prevent them using compliance-driven processes and quality checks.

Error 1: Participant Flow Inconsistencies

One of the most common issues is mismatch in the number of participants reported in the CSR vs. the registry’s participant flow section. Often, dropout counts, group allocation numbers, or “not treated” status are either omitted or misclassified.

Example: A sponsor reports 300 participants enrolled in the CSR, but only 285 are listed under “Started” in the ClinicalTrials.gov table, triggering a discrepancy flag.

Fix Strategy: Maintain a mapping file between raw dataset, CSR participant flow section, and registry summary. Ensure consistent terminology across all outputs. Use auto-validation tools within the Protocol Registration and Results System (PRS) to check totals.

Error 2: Baseline Data Incompleteness

Missing demographic or baseline characteristics can undermine the interpretability of outcomes. For example, failing to report gender breakdown or mean age per arm is a common error in CTIS uploads.

Corrective Action: Create a results summary template that includes mandatory fields as per registry specifications. Implement baseline checks within your medical writing review SOPs to ensure completeness prior to upload.

Error 3: Outcome Measure Discrepancies

This occurs when primary or secondary outcome measures listed in the registry do not match the final values presented in the CSR or are inconsistent across platforms. Even small shifts in timepoints, units, or populations analyzed can raise compliance issues.

Preventive Measure: Lock the protocol outcome definitions and registry fields early. Train teams on consistent use of endpoint terminology. Use the same SAS output table structure for both CSR and registry to reduce discrepancies.

Example Mapping Table

Error 4: Adverse Events Underreporting

Adverse events (AEs) are frequently misreported or incompletely disclosed due to complexity in coding and threshold application. CT.gov requires separate reporting of serious and non-serious AEs, both overall and per arm, with incidence thresholds. Failure to meet these standards can trigger public flags.

Correction Plan: Use MedDRA-based listings and confirm AE frequencies meet the reporting threshold (e.g., ≥5%). Validate that the CSR AE summary matches registry counts. Use PRS preview to verify expected tabular structure.

Error 5: Redaction and Data Privacy Violations

When posting lay summaries or results in the public domain, companies often neglect to remove sensitive personal data. Redaction errors can include naming trial sites, exposing investigator initials, or disclosing rare AE narratives that could lead to patient reidentification.

Compliance Action: Implement a two-level redaction review (medical and legal) before publishing. Use standard templates and refer to the EMA’s redaction guidance under Policy 0070. Consider using AI-powered redaction tools integrated into your disclosure platform.

CAPA Strategy for Disclosure Errors

When a significant registry error is discovered (e.g., underreporting of deaths, incorrect outcome values), implement a formal Corrective and Preventive Action (CAPA) procedure. A standard CAPA workflow involves:

1. Documenting the nature of the error and when it was identified.
2. Analyzing the root cause (e.g., version mismatch, training gap, miscommunication).
3. Updating the result fields with correct values.
4. Retraining involved teams on registry specifications.
5. Monitoring future uploads through QC checklists.

For examples of SOPs and CAPA templates, refer to PharmaSOP.in.

QA and Audit-Ready Processes

To maintain inspection readiness, QA teams should perform periodic audits of posted results. The checklist may include:

• Review of posting deadlines and actual upload dates
• Consistency check between CSR, registry, and protocol-defined endpoints
• Verification of PRS or CTIS validation success messages
• Archival of screenshots and system logs for audit trail

Additionally, establishing disclosure quality metrics—such as error rate per upload or cycle time from CSR finalization to public posting—can support continuous improvement initiatives.

Regulatory Trends and Inspection Insights

Agencies like the FDA and EMA are increasingly focusing on result disclosure accuracy during inspections. FDA Form 483 observations have cited inconsistencies between protocol-specified outcomes and posted summaries. The EMA also requires alignment of CTIS results with Module 5 documents of the Marketing Authorisation Application (MAA).

According to FDA guidance on ClinicalTrials.gov reporting, noncompliance can lead to notices of non-submission and potential civil monetary penalties. Early planning, clear roles, and checklists are essential to avoid such findings.

Conclusion

Inaccurate results reporting can have far-reaching implications—from regulatory penalties to loss of public trust. Understanding common mistakes such as data mismatches, baseline gaps, AE underreporting, and redaction errors is the first step. The second is establishing robust SOPs, QC workflows, and training modules for registry submissions.

By treating results disclosure as an integrated part of CSR and regulatory operations—not a post-hoc administrative task—sponsors can ensure transparency, compliance, and audit readiness. Tools like checklist-driven disclosure portals, redaction workflows, and cross-functional team training will form the cornerstone of future-ready disclosure strategy.

For further guidance, explore tools and regulatory harmonization documents at EMA or visit ClinicalStudies.in for real-world examples.

Understanding the EMA’s Oversight in EudraCT Compliance Monitoring

The Importance of EudraCT for Clinical Trial Transparency

EudraCT (European Union Drug Regulating Authorities Clinical Trials) is a centralized database established to fulfill transparency and accountability requirements for interventional clinical trials in the EU. Regulatory authorities, including the European Medicines Agency (EMA), rely on EudraCT to evaluate sponsor compliance, track study progress, and ensure that the rights and safety of trial participants are upheld. As the EU transitions toward CTIS under Regulation (EU) No 536/2014, the legacy responsibilities of EudraCT remain enforceable for trials initiated before January 31, 2023.

EMA’s Mandate and Scope of Oversight in EudraCT

The EMA’s role in EudraCT compliance focuses on several regulatory and operational functions, including:

• Maintaining and improving the functionality of the EudraCT database
• Issuing technical guidance to sponsors for result submission
• Monitoring data quality, completeness, and submission timelines
• Providing support to national competent authorities (NCAs) in auditing and enforcement

Through collaboration with NCAs and the European Commission, EMA ensures that sponsors adhere to Article 57 of Regulation (EC) No 726/2004 and related provisions requiring the timely submission and updating of clinical trial data. EMA’s oversight includes both preventive guidance and post-hoc enforcement actions, which may involve public disclosures of non-compliance.

Mechanisms Used by EMA to Track Compliance

EMA leverages multiple monitoring systems and tools to track sponsor adherence to trial registry expectations. These include:

• Automated Audit Logs: EudraCT maintains detailed audit trails of all user actions, submissions, and modifications to entries.
• Periodic Compliance Snapshots: EMA publishes aggregated data on registration status, summary result postings, and delay frequencies.
• Compliance Analytics Engine: Back-end algorithms review trends across therapeutic areas and trial phases to identify high-risk sponsors.

In one such report from 2022, EMA noted that over 31% of completed pediatric trials had not posted summary results within 12 months, prompting direct outreach to sponsors and letters of non-compliance.

Result Posting Requirements: EMA’s Compliance Enforcement

Per the 2012 European Commission guideline (2012/C 302/03), all interventional clinical trials must submit summary results to EudraCT within 12 months of the “end of trial” date. For pediatric trials, results must also be shared with the Paediatric Committee (PDCO). EMA enforces this requirement through:

• Sending warning notices to defaulting sponsors
• Publishing lists of non-compliant entities
• Escalating to NCAs for further regulatory action

Sponsors can avoid non-compliance by adopting centralized result submission processes and using built-in validation tools provided by EudraCT. For tools and best practices, visit PharmaGMP.in.

Case Example: EMA Enforcement Action for Non-Posting

In 2021, EMA identified a multinational CRO with over 45 overdue result submissions. A compliance audit revealed that the sponsor had inconsistently applied “end of trial” definitions and failed to monitor internal result timelines. The CRO was publicly named in the EMA’s transparency compliance report and required to submit an action plan to rectify all overdue postings within 90 days. Post-intervention analysis showed a 92% increase in compliance from the entity, showcasing EMA’s commitment to regulatory accountability.

EMA and National Competent Authorities: Division of Responsibilities

While EMA maintains and oversees the EudraCT platform, actual enforcement authority lies with the National Competent Authorities (NCAs) in each EU Member State. The EMA supports these bodies through technical tools, training materials, and compliance dashboards. Key roles include:

• EMA: Technical maintenance, guidance issuance, central data validation, transparency reporting
• NCAs: Trial authorization, sponsor inspections, regulatory penalties, compliance follow-up

This dual model ensures both centralized consistency and local enforcement power. For example, in Italy and France, NCAs routinely include EudraCT result submission status as part of GCP inspection checklists.

Transition to CTIS: How EMA’s Role Evolves

As the European Clinical Trials Regulation (EU CTR 536/2014) comes into full force, EMA’s role expands through the Clinical Trials Information System (CTIS). EMA is now responsible for:

• CTIS platform development and maintenance
• Managing user authentication and sponsor onboarding
• Supporting harmonized decision-making across Member States
• Public access to trial data through the CTIS portal

All trials initiated after 31 January 2023 must now use CTIS. However, EMA still monitors legacy trials registered in EudraCT until they are fully transitioned. The EudraCT interface remains accessible for amendment submissions, result postings, and corrections until final decommissioning post-2025.

How Sponsors Can Stay Compliant with EMA Monitoring

To align with EMA’s EudraCT compliance expectations, sponsors should implement the following strategies:

• Maintain a live tracker of all EudraCT trials and their “end of trial” dates
• Set internal deadlines for result summary preparation (target 9 months post-end)
• Use the EudraCT XML validation tool to pre-validate entries
• Ensure regular updates to trial status fields (e.g., recruitment end, completion)
• Designate a registry owner within Clinical Operations or Regulatory Affairs

EMA also recommends submitting queries through their support desk if sponsors face technical difficulties with XML uploads or public posting delays.

Conclusion

The EMA plays a critical role in ensuring that EudraCT functions not just as a registry, but as a transparency enabler and regulatory monitoring tool. Sponsors must treat their obligations seriously—not just to avoid penalties but to maintain public trust and regulatory goodwill.

With increased data analytics, public compliance dashboards, and support from NCAs, EMA is more equipped than ever to enforce timely and accurate registry updates. Sponsors should adopt proactive systems to stay audit-ready and transition seamlessly to CTIS.

To stay updated with the latest changes in trial registry compliance, visit pharmaValidation.in or review ongoing EMA initiatives at EMA’s official site.